{"id":65270,"date":"2026-05-14T13:21:58","date_gmt":"2026-05-14T05:21:58","guid":{"rendered":"https:\/\/flcube.com\/?p=65270"},"modified":"2026-05-14T13:21:59","modified_gmt":"2026-05-14T05:21:59","slug":"huadong-medicine-receives-nmpa-approval-for-hdm2017-adc-trial-in-colorectal-cancer-cadherin-17-targeting-therapy-shows-broad-solid-tumor-potential","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65270","title":{"rendered":"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a>) announced it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>HDM2017<\/strong>, an <strong>antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin)<\/strong>. The drug will be evaluated in combination with <strong>fruquintinib<\/strong> for the treatment of <strong>advanced colorectal cancer (CRC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones-amp-development-timeline\">Regulatory Milestones &amp; Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Jurisdiction<\/th><\/tr><\/thead><tbody><tr><td><strong>Advanced Solid Tumors Trial Clearance<\/strong><\/td><td>September 2025<\/td><td>China &amp; US<\/td><\/tr><tr><td><strong>Orphan Drug Designation<\/strong><\/td><td>March 2026<\/td><td>US FDA<\/td><\/tr><tr><td><strong>NMPA Clinical Trial Approval<\/strong><\/td><td>May 2026<\/td><td>China<\/td><\/tr><tr><td><strong>Indications for Orphan Status<\/strong><\/td><td>Biliary tract cancer, gastric cancer, pancreatic cancer<\/td><td>US FDA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-preclinical-data\">Drug Profile &amp; Preclinical Data<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Antibody drug conjugate (ADC)<\/strong> targeting <strong>Cadherin 17 (LI-cadherin)<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Selective targeting of CDH17-positive tumor cells with cytotoxic payload delivery<\/li>\n\n\n\n<li><strong>Preclinical Efficacy:<\/strong> Demonstrated <strong>potent anti-tumor effects<\/strong> in CDH17-positive models of:<\/li>\n\n\n\n<li>Colorectal cancer<\/li>\n\n\n\n<li>Pancreatic cancer<\/li>\n\n\n\n<li>Gastric cancer<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Showed <strong>favorable druggability, safety, and tolerability<\/strong> in animal studies<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> Will be assessed with <strong>fruquintinib<\/strong>, Huadong&#8217;s approved anti-angiogenic therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance-amp-market-opportunity\">Strategic Significance &amp; Market Opportunity<\/h2>\n\n\n\n<p>This NMPA approval represents a critical advancement in Huadong&#8217;s oncology pipeline, leveraging the company&#8217;s expertise in both targeted therapies and combination approaches. The <strong>triple orphan drug designation<\/strong> from the US FDA underscores the high unmet medical need in biliary tract, gastric, and pancreatic cancers.<\/p>\n\n\n\n<p><strong>Colorectal Cancer Context:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Advanced CRC remains challenging to treat with limited options after first-line therapy failure<\/li>\n\n\n\n<li>The combination of an ADC targeting tumor-specific antigens with anti-angiogenic therapy represents a novel approach<\/li>\n\n\n\n<li>CDH17 expression provides a potential biomarker for patient selection<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-commercial-outlook\">Competitive Landscape &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market:<\/strong> Rapidly expanding therapeutic class with multiple recent approvals across solid tumors<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> HDM2017&#8217;s targeting of <strong>Cadherin 17<\/strong> offers a unique mechanism compared to established ADC targets<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Dual regulatory pathway in China and US positions the asset for potential international development<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Combination with fruquintinib leverages Huadong&#8217;s existing commercial infrastructure and clinical experience<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of HDM2017. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a-5.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a (5).\"><\/object><a id=\"wp-block-file--media-dd4b5fc2-ad2e-45a2-b60b-212c94cd3538\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a-5.pdf\">\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a (5)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u534e\u4e1c\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u83b7\u5f97\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a-5.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-dd4b5fc2-ad2e-45a2-b60b-212c94cd3538\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,62,114,887],"class_list":["post-65270","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-huadong-medicine","tag-she-000963"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HDM2017, an antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin). The drug will be evaluated in combination with fruquintinib for the treatment of advanced colorectal cancer (CRC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65270\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for HDM2017, an antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin). The drug will be evaluated in combination with fruquintinib for the treatment of advanced colorectal cancer (CRC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65270\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T05:21:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T05:21:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65270#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65270\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential\",\"datePublished\":\"2026-05-14T05:21:58+00:00\",\"dateModified\":\"2026-05-14T05:21:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65270\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Huadong Medicine\",\"SHE: 000963\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65270#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65270\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65270\",\"name\":\"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T05:21:58+00:00\",\"dateModified\":\"2026-05-14T05:21:59+00:00\",\"description\":\"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HDM2017, an antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin). The drug will be evaluated in combination with fruquintinib for the treatment of advanced colorectal cancer (CRC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65270#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65270\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65270#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HDM2017, an antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin). The drug will be evaluated in combination with fruquintinib for the treatment of advanced colorectal cancer (CRC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65270","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential","og_description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HDM2017, an antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin). The drug will be evaluated in combination with fruquintinib for the treatment of advanced colorectal cancer (CRC).","og_url":"https:\/\/flcube.com\/?p=65270","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T05:21:58+00:00","article_modified_time":"2026-05-14T05:21:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65270#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65270"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential","datePublished":"2026-05-14T05:21:58+00:00","dateModified":"2026-05-14T05:21:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65270"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","Huadong Medicine","SHE: 000963"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65270#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65270","url":"https:\/\/flcube.com\/?p=65270","name":"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T05:21:58+00:00","dateModified":"2026-05-14T05:21:59+00:00","description":"Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for HDM2017, an antibody drug conjugate (ADC) targeting Cadherin 17 (LI-cadherin). The drug will be evaluated in combination with fruquintinib for the treatment of advanced colorectal cancer (CRC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65270#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65270"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65270#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine Receives NMPA Approval for HDM2017 ADC Trial in Colorectal Cancer \u2013 Cadherin 17-Targeting Therapy Shows Broad Solid Tumor Potential"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65270"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65270\/revisions"}],"predecessor-version":[{"id":65272,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65270\/revisions\/65272"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}